Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of PT010 in Moderate to Severe COPD
NCT03250182Phase 1Completed
- Sponsor
- Pearl Therapeutics
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD), sponsored by Pearl Therapeutics. Primary endpoints: Maximum Plasma Concentration at Day 8, Area Under the Plasma Concentration-time Curve (0-12h) at Day 8 and 1 more. Started Aug 2017; status: completed.
02
Drugs
Breztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03250182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250182.